Department of War Offers Antheia an $80 Million Conditional Loan for U.S. Drug-Ingredient Production. No Money Has Moved Yet

October 18, 2026

OSC announced “an $80 million conditional loan commitment with Antheia, Inc.” to scale domestic production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) for generic drugs. Antheia uses “bioengineered yeast to convert sugar directly into KSMs and APIs in a one-step fermentation process.” The release says Antheia “currently produces its pipeline of KSMs and APIs with contract manufacturing partners abroad” and that the financing “would enable Antheia to establish its U.S. manufacturing operations.”

Sources

• U.S. Department of War, “Department of War’s Office of Strategic Capital Signs $80 Million Conditional Loan Commitment With Antheia, Inc.” (October 17, 2026): https://www.war.gov/News/Releases/Release/Article/4628105/department-of-wars-office-of-strategic-capital-signs-80-million-conditional-loa/